Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Ajit Pratap Singh
Rana Hospital
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
1,520
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Immunogenicity and Tolerability of BBV154 (iNCOVACC®), an Intranasal SARS-CoV-2 Vaccine, Compared with Intramuscular Covaxin® in Healthy Adults: A Randomised, Open-Label, Phase 3 Clinical Trial
Number of pages: 33
Posted: 31 Jan 2023
Chandramani Singh
,
Savita Verma
,
Prabhakar Reddy
,
Michael S. Diamond
,
David T. Curiel
,
Chintan Patel
,
Manish Kumar Jain
,
Sagar Vivek Redkar
,
Amit Suresh Bhate
,
Vivek Gundappa
,
Rambabu Konatham
,
Leelabati Toppo
,
Aniket Chandrakant Joshi
,
Jitendra Singh Kushwah
, Ajit Pratap Singh,
Shilpa Gaidhane
,
Krishna Mohan Vadrevu
and
BBV154 Study Group
All India Institute of Medical Sciences (AIIMS), Bhopal, Pt. B.D. Sharma Postgraduate Institute of Medical Sciences, Nizams Institute of Medical Sciences, Washington University School of Medicine - Department of Medicine, Washington University in St. Louis - Department of Radiation Oncology, Aatman Hospital, Maharaja Agrasen Super Speciality Hospital, Redkar Hospital and Research Centre, Jeevan Rekha Hospital, Rajarajeswari Medical College and Hospital, Visakha Institute of Medical Science, Malla Reddy Narayana Multispeciality Hospital, ONP Hospitals, Prakhar Hospital, Rana Hospital, Acharya Vinoba Bhave Rural Hospital, Bharat Biotech International Ltd and Independent
Downloads
1,520
(30,910)
View PDF
Download
Abstract:
SARS-COV-2, COVID-19, vaccine, intranasal, intramuscular, immunogenicity, reactogenicity
Feedback